Rademikibart

Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases.